Sangamo Biosciences (SGMO) Receives a Hold from Wedbush


Wedbush analyst Liana Moussatos reiterated a Hold rating on Sangamo Biosciences (SGMO) yesterday and set a price target of $11. The company’s shares closed yesterday at $10.74, close to its 52-week low of $9.

According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -9.5% and a 34.3% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Liquidia Technologies Inc.

Sangamo Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $14.50, representing a 35.0% upside. In a report issued on November 9, Guggenheim also downgraded the stock to Hold with a $18 price target.

.

See today’s analyst top recommended stocks >>

Based on Sangamo Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $12.84 million. In comparison, last year the company had a GAAP net loss of $12.35 million.

Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SGMO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sangamo Therapeutics, Inc. researches and develops transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. Lanphier II on June 22, 1995 and is headquartered in Richmond, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts